Cargando…

The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study

OBJECTIVES: Owing to novel therapy strategies in epidermal growth factor receptor (EGFR)-mutated patients, molecular analysis of the EGFR and KRAS genome has become crucial for routine diagnostics. Till date these data have been derived mostly from clinical trials, and thus collected in pre-selected...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boch, Christian, Kollmeier, Jens, Roth, Andreas, Stephan-Falkenau, Susann, Misch, Daniel, Grüning, Wolfram, Bauer, Torsten Thomas, Mairinger, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2013
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641502/ https://www.ncbi.nlm.nih.gov/pubmed/23558737 http://dx.doi.org/10.1136/bmjopen-2013-002560

Ejemplares similares

Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)—A Single Center, Retrospective Observational Study
por: Stephan-Falkenau, Susann, et al.
Publicado: (2022)

Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy
por: Wessolly, Michael, et al.
Publicado: (2022)

Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer
por: Misch, Daniel, et al.
Publicado: (2015)

Comparison of different semi-automated cfDNA extraction methods in combination with UMI-based targeted sequencing
por: Streubel, Anna, et al.
Publicado: (2019)

Integrated Clinical, Molecular and Immunological Characterization of Pulmonary Sarcomatoid Carcinomas Reveals an Immune Escape Mechanism That May Influence Therapeutic Strategies
por: Stephan-Falkenau, Susann, et al.
Publicado: (2023)

Morphometrical analysis of transbronchial cryobiopsies
por: Griff, Sergej, et al.
Publicado: (2011)

Erratum to: Morphometrical analysis of transbronchial cryobiopsies
por: Griff, Sergej, et al.
Publicado: (2016)

A Novel Epitope Quality-Based Immune Escape Mechanism Reveals Patient’s Suitability for Immune Checkpoint Inhibition
por: Wessolly, Michael, et al.
Publicado: (2020)

Autoimmune disorders and paraneoplastic syndromes in thymoma
por: Blum, Torsten Gerriet, et al.
Publicado: (2020)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
por: Moreno, Silvia, et al.
Publicado: (2021)

Determinants of plasma calretinin in patients with malignant pleural mesothelioma
por: Lehnert, Martin, et al.
Publicado: (2020)

Diagnostic yield of transbronchial cryobiopsy in non-neoplastic lung disease: a retrospective case series
por: Griff, Sergej, et al.
Publicado: (2014)

Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors
por: Nardo, Giorgia, et al.
Publicado: (2021)

EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients
por: Villalva, Claire, et al.
Publicado: (2013)

KRAS above and beyond – EGFR in pancreatic cancer
por: Siveke, Jens T., et al.
Publicado: (2012)

Short report: Performance evaluation of the Idylla™ KRAS and EGFR mutation tests on paraffin-embedded cytological NSCLC samples
por: Offerman, Saskia, et al.
Publicado: (2021)

Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
por: Brcic, Luka, et al.
Publicado: (2016)

KRAS in NSCLC: State of the Art and Future Perspectives
por: Cascetta, Priscilla, et al.
Publicado: (2022)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA
por: Del Re, Marzia, et al.
Publicado: (2016)

Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumour cell content by 454 deep sequencing
por: Moskalev, Evgeny A., et al.
Publicado: (2013)

Snapback Primer Mediated Clamping PCR for Detection of EGFR and KRAS Mutations in NSCLC Patients by High Resolution Melting Analysis
por: Sun, Haiyan, et al.
Publicado: (2014)

KRAS(G12C)/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma
por: Frost, Nikolaj, et al.
Publicado: (2021)

The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy
por: Friedlaender, Alex, et al.
Publicado: (2021)

High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia
por: Heriyanto, Didik Setyo, et al.
Publicado: (2022)

One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy
por: Hager, Thomas, et al.
Publicado: (2023)

Implications of KRAS mutations in acquired resistance to treatment in NSCLC
por: Del Re, Marzia, et al.
Publicado: (2017)

EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma
por: Smits, Alexander J. J., et al.
Publicado: (2012)

A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses
por: Koopman, Bart, et al.
Publicado: (2021)

Treating KRAS-mutant NSCLC: latest evidence and clinical consequences
por: Garrido, Pilar, et al.
Publicado: (2017)

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC
por: Weidhaas, Joanne B., et al.
Publicado: (2023)

Poor prognosis of NSCLC located in lower lobe is partly mediated by lower frequency of EGFR mutations
por: Lee, Hyun Woo, et al.
Publicado: (2020)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

Unexpected responses to EGFR inhibition in NSCLC
por: Stella, Giulia M., et al.
Publicado: (2015)

Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC
por: Gaber, Rania, et al.
Publicado: (2014)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

The Frequency of EGFR and KRAS Mutations in the Turkish Population with Non-small Cell Lung Cancer and their Response to Erlotinib Therapy
por: Demiray, A, et al.
Publicado: (2018)

BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC
por: Jauset, Toni, et al.
Publicado: (2018)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sealb1b4qts6ekb791tni7e4bc